SCHEMBL19945526

SCHEMBL19945526

CCSc1nc(N)c(NC)c(N(C=O)Cc2ccc(Cl)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADORA3 P0DMS8 1/20 0.36
▸ ADORA1 P30542 1/20 0.36
▸ MEN1 O00255 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ HSP90AA1 P07900 1/20 0.34
▸ LMNA P02545 2/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ HPGD P15428 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ HSD17B10 Q99714 1/20 0.32
▸ MAPK1 P28482 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ SIRT2 Q8IXJ6 1/20 0.31
▸ ABCB1 P08183 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19945228 0.90 RAB9A (0.35) MEN1KMT2AHSP90AA1LMNAL3MBTL1
SCHEMBL19945582 0.89 HTT (0.34) ADORA3MEN1KMT2ALMNAKDM4E
SCHEMBL21318940 0.82 ADORA3 (0.42) ADORA3ADORA1MEN1KMT2ALMNA
SCHEMBL19945779 0.82 MEN1 (0.36) MEN1KMT2ALMNAKDM4EL3MBTL1
SCHEMBL21318984 0.81 KMT2A (0.34) ADORA3MEN1KMT2ALMNAL3MBTL1
SCHEMBL21318963 0.81 TSHR (0.31) L3MBTL1MAPK1
SCHEMBL19945665 0.80 ABCB1 (0.38) ADORA3ADORA1KMT2AALDH1A1MAPT
SCHEMBL23019016 0.79 MAP4K4 (0.35) LMNAKDM4EHTTALDH1A1RAB9A
SCHEMBL21318986 0.77 ADORA3 (0.31) ADORA3ADORA1MEN1KMT2AKDM4E
SCHEMBL21318947 0.77 USP28 (0.39) ADORA3ADORA1LMNAL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3970750-A1 COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR F. Hoffmann-La Roche AG (CH) 2022-03-23 — — EP disclosed
EP-3512556-B1 COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR HOFFMANN LA ROCHE (CH) 2021-08-18 — — EP disclosed
EP-3865482-A1 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2021-08-18 — — EP disclosed
EP-3504210-B1 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2021-02-24 — — EP disclosed
EP-3294740-B1 NOVEL SULFONIMIDOYLPURINONE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2019-09-04 — — EP disclosed
WO-2018050571-A1 COMBINED TREATMENT WITH A TLR7 AGONIST AND AN HBV CAPSID ASSEMBLY INHIBITOR F. HOFFMANN-LA ROCHE AG (CH) 2018-03-22 — — WO disclosed
WO-2018041763-A1 7-SUBSTITUTED SULFONIMIDOYLPURINONE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2018-03-08 — — WO disclosed
Send feedback